Literature DB >> 24462898

Hydrogel-nanoparticle composites for optically modulated cancer therapeutic delivery.

Laura E Strong1, Shreyas N Dahotre1, Jennifer L West2.   

Abstract

A poly(N-isopropylacrylamide-co-acrylamide) (NIPAAm-co-AAm) hydrogel with near-infrared (NIR) absorbing silica-gold nanoshells was designed as a platform for pulsatile delivery of cancer therapeutics. This hydrogel was designed to have a lower critical solution temperature (LCST) above physiologic temperature, such that the material will transition from a hydrated state to a collapsed state above ~40°C. Additionally, the silica-gold nanoshells used were designed to have a peak extinction coefficient in the NIR, where penetration of light through tissue is maximal. This heat-triggered material phase transition of the composite was found to follow exposure of NIR light, indicating the ability of the NIR absorption by the nanoshells to sufficiently drive this transition. The composite material was loaded with either doxorubicin or a DNA duplex (a model nucleic acid therapeutic), two cancer therapeutics with differing physical and chemical properties. Release of both therapeutics was dramatically enhanced by NIR light exposure, causing 2-5x increase in drug release. Drug delivery profiles were influenced by both the molecular size of the drug as well as its chemical properties. The DNA therapeutic showed slower rates of nonspecific delivery by passive diffusion due to its larger size. Additionally, only 70% of the more hydrophobic doxorubicin was released from the material, whereas the more hydrophilic DNA showed over 90% release. Further, hydrogel composites were used to deliver the doxorubicin to CT.26-WT colon carcinoma cells, eliciting a therapeutic response. This work validates the potential application for this material in site-specific cancer therapeutic delivery.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer therapeutics; Hydrogel; N-isopropylacrylamide; Nanoparticle; Thermally responsive

Mesh:

Substances:

Year:  2014        PMID: 24462898      PMCID: PMC4077349          DOI: 10.1016/j.jconrel.2014.01.014

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  36 in total

1.  Immunotargeted nanoshells for integrated cancer imaging and therapy.

Authors:  Christopher Loo; Amanda Lowery; Naomi Halas; Jennifer West; Rebekah Drezek
Journal:  Nano Lett       Date:  2005-04       Impact factor: 11.189

2.  Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy.

Authors:  F Lévi; R Zidani; J L Misset
Journal:  Lancet       Date:  1997-09-06       Impact factor: 79.321

Review 3.  Cancer treatment and survivorship statistics, 2012.

Authors:  Rebecca Siegel; Carol DeSantis; Katherine Virgo; Kevin Stein; Angela Mariotto; Tenbroeck Smith; Dexter Cooper; Ted Gansler; Catherine Lerro; Stacey Fedewa; Chunchieh Lin; Corinne Leach; Rachel Spillers Cannady; Hyunsoon Cho; Steve Scoppa; Mark Hachey; Rebecca Kirch; Ahmedin Jemal; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2012-06-14       Impact factor: 508.702

4.  Potential for therapy of drugs and hyperthermia.

Authors:  G M Hahn
Journal:  Cancer Res       Date:  1979-06       Impact factor: 12.701

5.  Gold nanoshell bioconjugates for molecular imaging in living cells.

Authors:  Christopher Loo; Leon Hirsch; Min-Ho Lee; Emmanuel Chang; Jennifer West; Naomi Halas; Rebekah Drezek
Journal:  Opt Lett       Date:  2005-05-01       Impact factor: 3.776

6.  Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells.

Authors:  F A Fornari; J K Randolph; J C Yalowich; M K Ritke; D A Gewirtz
Journal:  Mol Pharmacol       Date:  1994-04       Impact factor: 4.436

7.  Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells.

Authors:  Raquel T Lima; Luís M Martins; José E Guimarães; Clara Sambade; M Helena Vasconcelos
Journal:  Cancer Gene Ther       Date:  2004-05       Impact factor: 5.987

8.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.

Authors:  Y Matsumura; H Maeda
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701

9.  A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity.

Authors:  Jesper B Bramsen; Maria B Laursen; Anne F Nielsen; Thomas B Hansen; Claus Bus; Niels Langkjaer; B Ravindra Babu; Torben Højland; Mikhail Abramov; Arthur Van Aerschot; Dalibor Odadzic; Romualdas Smicius; Jens Haas; Cordula Andree; Jharna Barman; Malgorzata Wenska; Puneet Srivastava; Chuanzheng Zhou; Dmytro Honcharenko; Simone Hess; Elke Müller; Georgii V Bobkov; Sergey N Mikhailov; Eugenio Fava; Thomas F Meyer; Jyoti Chattopadhyaya; Marino Zerial; Joachim W Engels; Piet Herdewijn; Jesper Wengel; Jørgen Kjems
Journal:  Nucleic Acids Res       Date:  2009-03-12       Impact factor: 16.971

10.  siRNA inhibition of telomerase enhances the anti-cancer effect of doxorubicin in breast cancer cells.

Authors:  Xuejun Dong; Anding Liu; Cindy Zer; Jianguo Feng; Zhuan Zhen; Mingfeng Yang; Li Zhong
Journal:  BMC Cancer       Date:  2009-05-05       Impact factor: 4.430

View more
  10 in total

Review 1.  Technologies for controlled, local delivery of siRNA.

Authors:  Samantha M Sarett; Christopher E Nelson; Craig L Duvall
Journal:  J Control Release       Date:  2015-11-28       Impact factor: 9.776

2.  Photo-triggerable Hydrogel-Nanoparticle Hybrid Scaffolds for Remotely Controlled Drug Delivery.

Authors:  Shreyas Shah; Pijus K Sasmal; Ki-Bum Lee
Journal:  J Mater Chem B       Date:  2014       Impact factor: 6.331

Review 3.  Programmable biomaterials for dynamic and responsive drug delivery.

Authors:  Anna Stejskalová; Mehrdad T Kiani; Benjamin D Almquist
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-13

Review 4.  Specialty Tough Hydrogels and Their Biomedical Applications.

Authors:  Stephanie Fuchs; Kaavian Shariati; Minglin Ma
Journal:  Adv Healthc Mater       Date:  2019-12-17       Impact factor: 9.933

5.  pH/NIR Light-Controlled Multidrug Release via a Mussel-Inspired Nanocomposite Hydrogel for Chemo-Photothermal Cancer Therapy.

Authors:  Amin GhavamiNejad; Melisa SamariKhalaj; Ludwig Erik Aguilar; Chan Hee Park; Cheol Sang Kim
Journal:  Sci Rep       Date:  2016-09-20       Impact factor: 4.379

6.  Peritumoral implantation of hydrogel-containing nanoparticles and losartan for enhanced nanoparticle penetration and antitumor effect.

Authors:  Haijun Shen; Qianqian Gao; Qi Ye; Shiyun Yang; Yuqian Wu; Qin Huang; Xiaona Wang; Zhenhua Sun
Journal:  Int J Nanomedicine       Date:  2018-11-13

7.  Short duration cancer treatment: inspired by a fast bio-resorbable smart nano-fiber device containing NIR lethal polydopamine nanospheres for effective chemo-photothermal cancer therapy.

Authors:  Francis O Obiweluozor; Gladys A Emechebe; Arjun Prasad Tiwari; Ju Yeon Kim; Chan Hee Park; Cheol Sang Kim
Journal:  Int J Nanomedicine       Date:  2018-10-12

8.  Hydrogel-Coated Near Infrared Absorbing Nanoshells as Light-Responsive Drug Delivery Vehicles.

Authors:  Laura E Strong; Jennifer L West
Journal:  ACS Biomater Sci Eng       Date:  2015-06-10

9.  Changes in Optical Properties of Plasmonic Nanoparticles in Cellular Environments are Modulated by Nanoparticle PEGylation and Serum Conditions.

Authors:  Allen L Chen; Meredith A Jackson; Adam Y Lin; Elizabeth R Figueroa; Ying S Hu; Emily R Evans; Vishwaratn Asthana; Joseph K Young; Rebekah A Drezek
Journal:  Nanoscale Res Lett       Date:  2016-06-18       Impact factor: 4.703

Review 10.  Recent Advances in Nanotechnology with Nano-Phytochemicals: Molecular Mechanisms and Clinical Implications in Cancer Progression.

Authors:  Bonglee Kim; Ji-Eon Park; Eunji Im; Yongmin Cho; Jinjoo Lee; Hyo-Jung Lee; Deok-Yong Sim; Woon-Yi Park; Bum-Sang Shim; Sung-Hoon Kim
Journal:  Int J Mol Sci       Date:  2021-03-30       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.